Table 1.
Baseline demographics
| |
Cohort 1 |
Cohort 2 |
Overall |
|---|---|---|---|
| (n = 9) | (n = 10) | (n = 19) | |
|
Mean age, years (range) |
50.0 (36 to 71) |
50.7 (38 to 67) |
50.4 (36 to 71) |
|
ECOG status, n |
|
|
|
| 0/1/2 |
8/1/0 |
5/5/0 |
13/6/0 |
|
Previous chemotherapy regimens, n (%) |
|
|
|
| Any adjuvant regimen |
5 (56) |
9 (90) |
14 (74) |
| Taxanea |
7 (78) |
8 (80) |
15 (79) |
| First-line setting |
2 (22) |
0 |
2 (11) |
| Adjuvant setting |
2 (22) |
6 (60) |
8 (42) |
| Neo-adjuvant setting |
3 (33) |
1 (10) |
4 (21) |
| Metastatic setting |
0 |
2 (20) |
2 (11) |
| Anthracycline |
6 (67) |
6 (60) |
12 (63) |
| Capecitabine | 1 (11) | 0 | 1 (5) |
ECOG, Eastern Cooperative Group.
aOne patient in cohort 2 had previously received taxane chemotherapy in both adjuvant and metastatic settings.